TAKEDA PHARMACEUTICAL COMPANY LIMITED Financials Takeda Pharmaceutical Company Limited London S.E.
Equities
0A87
US8740602052
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.3 USD | +2.30% |
|
+1.66% | -6.51% |
| Jul. 09 | Takeda Issues New Shares, Disposes of Treasury Shares Under Incentive Scheme | MT |
| Jul. 03 | Blackstone selling Japan drugmaker Alinamin to MBK Partners | RE |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,153,364 | 6,229,971 | 5,423,454 | 6,762,204 | 6,564,378 | 6,719,804 | - | - |
| Enterprise Value (EV) 1 | 9,609,054 | 9,862,522 | 8,919,170 | 10,611,015 | 10,950,330 | 10,827,939 | 10,569,509 | 10,413,459 |
| P/E ratio | 118 x | 16.6 x | 23.8 x | 21.3 x | 45.4 x | 57.9 x | 31.2 x | 23.4 x |
| Yield | 5.44% | 4.52% | 5.15% | 4.14% | 4.49% | 4.6% | 4.7% | 4.95% |
| Capitalization / Revenue | 1.57 x | 1.95 x | 1.52 x | 1.68 x | 1.54 x | 1.56 x | 1.54 x | 1.51 x |
| EV / Revenue | 2.92 x | 3.08 x | 2.5 x | 2.63 x | 2.57 x | 2.52 x | 2.43 x | 2.34 x |
| EV / EBITDA | 14 x | 9.23 x | 8.54 x | 9.19 x | 11.6 x | 9.9 x | 9.02 x | 8.41 x |
| EV / FCF | 9.99 x | 16 x | 8.92 x | 28.7 x | 43.4 x | 16.7 x | 16.7 x | 16.2 x |
| FCF Yield | 10% | 6.26% | 11.2% | 3.49% | 2.31% | 5.98% | 6.01% | 6.18% |
| Price to Book | 1.09 x | 1.2 x | 0.95 x | 1.06 x | 0.9 x | 0.96 x | 0.97 x | 0.96 x |
| Nbr of stocks (in thousands) | 1,557,849 | 1,563,355 | 1,550,444 | 1,554,530 | 1,568,924 | 1,584,859 | - | - |
| Reference price 2 | 3,308 | 3,985 | 3,498 | 4,350 | 4,184 | 4,240 | 4,240 | 4,240 |
| Announcement Date | 5/13/20 | 5/11/21 | 5/11/22 | 5/11/23 | 5/9/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,291,200 | 3,197,812 | 3,569,006 | 4,027,478 | 4,263,762 | 4,294,656 | 4,356,461 | 4,453,575 |
| EBITDA 1 | 684,057 | 1,068,940 | 1,043,995 | 1,154,905 | 942,077 | 1,094,081 | 1,171,629 | 1,238,658 |
| EBIT 1 | 100,400 | 509,269 | 460,844 | 490,505 | 214,100 | 290,540 | 416,776 | 509,859 |
| Operating Margin | 3.05% | 15.93% | 12.91% | 12.18% | 5.02% | 6.77% | 9.57% | 11.45% |
| Earnings before Tax (EBT) 1 | -60,754 | 366,235 | 302,571 | 375,090 | 52,791 | 113,291 | 285,481 | 365,545 |
| Net income 1 | 44,200 | 376,005 | 230,059 | 317,017 | 144,067 | 116,257 | 215,584 | 284,685 |
| Net margin | 1.34% | 11.76% | 6.45% | 7.87% | 3.38% | 2.71% | 4.95% | 6.39% |
| EPS 2 | 28.00 | 240.7 | 147.1 | 204.3 | 92.09 | 73.22 | 135.9 | 181.3 |
| Free Cash Flow 1 | 961,871 | 617,401 | 999,853 | 370,054 | 252,482 | 647,920 | 634,805 | 643,617 |
| FCF margin | 29.23% | 19.31% | 28.01% | 9.19% | 5.92% | 15.09% | 14.57% | 14.45% |
| FCF Conversion (EBITDA) | 140.61% | 57.76% | 95.77% | 32.04% | 26.8% | 59.22% | 54.18% | 51.96% |
| FCF Conversion (Net income) | 2,176.18% | 164.2% | 434.61% | 116.73% | 175.25% | 557.32% | 294.46% | 226.08% |
| Dividend per Share 2 | 180.0 | 180.0 | 180.0 | 180.0 | 188.0 | 195.2 | 199.4 | 209.9 |
| Announcement Date | 5/13/20 | 5/11/21 | 5/11/22 | 5/11/23 | 5/9/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S2 | 2021 S1 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,631,000 | 1,590,785 | 1,794,400 | 901,294 | 873,289 | 972,465 | 1,002,340 | 1,974,800 | 1,096,551 | 956,200 | 1,058,618 | 1,043,089 | 2,101,707 | 1,111,200 | 1,050,869 | 1,074,362 | 1,083,543 | 2,126,400 | 1,141,543 | 1,063,671 | 1,067,000 | 2,137,000 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | 249,972 | 340,072 | 133,355 | - | 291,975 | 176,675 | 320,925 | 282,725 | - | 368,925 | 202,525 | - | - |
| EBIT 1 | 50,100 | 215,588 | 346,000 | 116,484 | -1,619 | 150,515 | 104,485 | 255,000 | 146,990 | 88,600 | 168,571 | -49,341 | 119,230 | 104,900 | -10,055 | 95,680 | 73,125 | 137,550 | 74,350 | 19,425 | 121,000 | 239,500 |
| Operating Margin | 3.07% | 13.55% | 19.28% | 12.92% | -0.19% | 15.48% | 10.42% | 12.91% | 13.4% | 9.27% | 15.92% | -4.73% | 5.67% | 9.44% | -0.96% | 8.91% | 6.75% | 6.47% | 6.51% | 1.83% | 11.34% | 11.21% |
| Earnings before Tax (EBT) 1 | -33,197 | 125,561 | 284,425 | 72,193 | -54,047 | 155,473 | 64,549 | 220,022 | 107,153 | 47,900 | 135,033 | -95,980 | 39,053 | 61,300 | -47,500 | 70,590 | 44,187 | 57,650 | 35,554 | -21,513 | 79,500 | 156,500 |
| Net income 1 | 11,000 | 86,548 | 183,600 | 57,769 | -11,358 | 105,014 | 61,786 | 166,800 | 119,127 | 31,100 | 89,395 | -48,030 | 41,365 | 105,700 | -3,000 | 64,390 | 40,154 | 59,800 | 33,654 | -15,713 | 61,000 | 120,500 |
| Net margin | 0.67% | 5.44% | 10.23% | 6.41% | -1.3% | 10.8% | 6.16% | 8.45% | 10.86% | 3.25% | 8.44% | -4.6% | 1.97% | 9.51% | -0.29% | 5.99% | 3.71% | 2.81% | 2.95% | -1.48% | 5.72% | 5.64% |
| EPS 2 | - | 55.45 | 117.0 | 37.01 | -6.950 | 67.94 | 40.06 | 108.0 | 76.70 | 20.03 | 57.51 | -31.00 | 26.51 | 67.38 | -1.920 | 38.70 | 23.80 | 47.50 | 24.35 | -15.33 | 38.90 | 76.80 |
| Dividend per Share | - | 90.00 | 90.00 | - | - | - | - | - | - | - | - | 94.00 | 94.00 | - | 94.00 | - | - | - | - | - | - | - |
| Announcement Date | 5/13/20 | 10/29/20 | 10/28/21 | 2/3/22 | 5/11/22 | 7/28/22 | 10/27/22 | 10/27/22 | 2/2/23 | 5/11/23 | 7/27/23 | 10/26/23 | 10/26/23 | 2/1/24 | 5/9/24 | - | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 4,455,690 | 3,632,551 | 3,495,716 | 3,848,811 | 4,385,952 | 4,108,135 | 3,849,705 | 3,693,655 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 6.514 x | 3.398 x | 3.348 x | 3.333 x | 4.656 x | 3.755 x | 3.286 x | 2.982 x |
| Free Cash Flow 1 | 961,871 | 617,401 | 999,853 | 370,054 | 252,482 | 647,920 | 634,805 | 643,617 |
| ROE (net income / shareholders' equity) | 0.9% | 7.6% | 4.2% | 5.3% | 2.1% | 1.24% | 2.78% | 4.21% |
| ROA (Net income/ Total Assets) | -0.46% | 2.85% | 2.32% | 2.76% | 0.36% | 0.64% | 1.48% | 2.16% |
| Assets 1 | -9,710,018 | 13,209,937 | 9,918,859 | 11,467,260 | 39,661,656 | 18,176,465 | 14,576,332 | 13,198,170 |
| Book Value Per Share 2 | 3,032 | 3,309 | 3,666 | 4,087 | 4,636 | 4,430 | 4,367 | 4,417 |
| Cash Flow per Share 2 | 403.0 | 599.0 | 520.0 | 632.0 | 557.0 | 643.0 | 644.0 | 666.0 |
| Capex 1 | 217,710 | 236,468 | 186,037 | 633,689 | 480,730 | 321,692 | 285,455 | 293,509 |
| Capex / Sales | 6.61% | 7.39% | 5.21% | 15.73% | 11.27% | 7.49% | 6.55% | 6.59% |
| Announcement Date | 5/13/20 | 5/11/21 | 5/11/22 | 5/11/23 | 5/9/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,240
JPY
Average target price
4,744
JPY
Spread / Average Target
+11.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.53% | 856B | |
| +38.95% | 631B | |
| -3.66% | 359B | |
| +15.06% | 325B | |
| +9.18% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.67% | 177B | |
| +2.47% | 165B |
- Stock Market
- Equities
- 4502 Stock
- 0A87 Stock
- Financials Takeda Pharmaceutical Company Limited
